Zim Laboratories Ltd. · NSE:ZIMLAB
Zim Laboratories — 9MFY23 Earnings Presentation
23 slides from Zim Laboratories's earnings presentation, Feb 3, 2023
Slide 1: Exchange cover letter: Corporate Presentation 9M FY 2022-23
Zeal & Innovation in Medicine Ref No.: ZLL/CS/BM/BSE Date : 03.02.2023 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai — 400 051 Company Co
Slide 2: Zim Laboratories Limited Corporate Presentation: 9MFY23
ZIM LABORATORIES LIMITED CORPORATE PRESENTATION : 9MFY23 FEBRUARY 2023
Slide 3: Contents
CONTENTS CORPORATE OVERVIEW FINANCIAL OVERVIEW CORPORATE INFORMATION 05 OUR BUSINESS 14 TOTAL OPERATING INCOME 20 SHAREHOLDING 06 BUSINESS HIGHLIGHTS : Q3FY23 15 EBITDA 21 SHARE PRICE MOVEMENT 07 FINANCIAL HIGHLIGHTS 16 PROFIT AFTER TAX 08 EXPORTS BUSINESS 17 RESEARCH AND DEVELOPMENT 09 PFI EXPORTS
Slide 4: Safe Harbour
SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall f
Slide 5: Company Overview
zm Zeal & Innovation in Medicine COMPANY OVERVIEW
Slide 6: Our Business
OUR BUSINESS ZIM develops and supplies differentiated generic Pharmaceutical and We are presently focussed on developing unique differentiated Nutraceutical products in Finished Formulations (FF) and Pre- Novel Innovative Products (NIPs) for Developed and Formulation Intermediates (PFI) in certain k
Slide 7: Business Highlights: Q3FY23
BUSINESS HIGHLIGHTS : Q3FY23 In 3 NIP products, Pivotal BE studies were completed for the EU markets; 75% of our business was from Pharmaceutical products and the this is part of 10 NIPs that are at various stages of Dossier completion balance 25% from Nutraceuticals and registration for the Develop
Slide 8: Financial Highlights
FINANCIAL HIGHLIGHTS 9MFY23 Q3FY23 Total Operating Income grew 28.3% YoY to Rs2,931Mn in 9MFY23 (from Total Operating Income for Q3FY23 was Rs1,010Mn, up 16.5% YoY and Rs2,284 in 9MFY22) up 1.6% QoQ EBITDA for 9MFY23 grew to Rs423Mn from Rs290Mn in 9MFY22; margins EBITDA for Q3FY23 was Rs155Mn, up 3
Slide 9: Exports Business
EXPORTS BUSINESS Exports business for 9MFY23 was Rs 2,483Mn, up 30.5% from Rs 1,902 Mn in 9MFY22 9MFY22 223 Contribution from Exports was 85% of our Total Operating Income 159 10% 7% Key regions for Exports during the year were MENA,SE Asia, Europe and Africa 2,483 880 1,902 845 83% 799 9MFY23 246 7
Slide 10: PFI Exports
PFI EXPORTS Our Pre-Formulation Intermediaries (PFI) business grew 40% in 9MFY23 vs 9MFY22 Exports of PFI comprise of 62% of our Total Operating Income PFI exports are based on deep-rooted, long-term relationship with our partners; Key regions for PFI business are Asia, Europe and MENA 1,828 687 40%
Slide 11: Finished Formulation (FF) Exports
FINISHED FORMULATION (FF) EXPORTS Finished Formulations Exports business has grown by 9% in 9MFY23 vs 9MFY22 Exports of FF comprise of 21% of our Total Operating Income; this business is being strengthened through further investment in marketing team, offices, registration and upgraded Dossiers 3 Th
Slide 12: Domestic and Other Business
DOMESTIC AND OTHER BUSINESS 9MFY22 (RS. 382 MN) 159 42% 94 Our “Domestic and Other Business” comprise 15% of our Total Operating Income 25% and has grown to Rs 448Mn (9MFY23) from Rs382Mn (9MFY22) The Domestic Business includes sale to Central/ State Government and Other Agencies (under “Jan Aushadh
Slide 13: Oral Thin Films
ORAL THIN FILMS During Q3FY23, our partners received 3 Marketing Authorisations in the Netherlands, Croatia and Malta for marketing Sildenafil Citrate 50 mg OTF dosage; registration on ZIM’s Dossier (this is in addition to the MA granted for Rizatriptan OTF dosage for EU) An MA was also granted to o
Slide 14: Financial Overview
zm Zeal & Innovation in Medicine FINANCIAL OVERVIEW
Slide 15: Total Operating Income
TOTAL OPERATING INCOME 45 27 2,931 2,284 Total Operating Income grew to Rs2,931Mn from Rs2,284Mn in 9MFY22 9MFY23 9MFY22; a growth of 28.3% YoY Total Operating Income Other operating income Business related ”Other Operating Income” incl. licensing fees and export incentives grew to Rs45Mn in 9MFY23
Slide 16: EBITDA
EBITDA In Rs. Mn and as % of Total Operating Income 423 EBITDA grew from Rs 290Mn in 9MFY22 to Rs 423Mn in 9MFY23 14.4% in spite of increase in operating costs and employee costs 290 Operating costs in the last few quarters has seen an upward 12.7% trend on account of significant increase in oil pri
Slide 17: Profit After Tax
PROFIT AFTER TAX In Rs. Mn and as % of Total Operating Income 172 5.9% 76 3.3% Profit After Tax(PAT) grew to Rs 172Mn in 9MFY23 compared to Rs 76Mn in 9MFY22 9MFY22 9MFY23 Our finance cost for Q3FY23 declined to Rs 16Mn vs Rs 18Mn in In Rs. Mn and as % of Total Operating Income Q3FY22 due to decreas
Slide 18: Research & Development
RESEARCH & DEVELOPMENT R&D Expense Mix (In % of total R&D expenses) 4% 19% Our R&D expenses were 6.2% of Total Operating Income for 9MFY23 34% 9% Around 19% of the expenses were incurred on BE and other study etc. , 72% were incurred on salary, materials, and the balance was on capitalized expenses
Slide 19: Income Statement
INCOME STATEMENT Key Financial Highlights: Income Statement (Rs. Mn) Particulars 9MFY23 9MFY22 Change % (YoY) Q3FY23 Q3FY22 Change % (YoY) Total Operating Income 2,931 2,284 28.3% 1,010 867 16.5% Other Income 57 28 105.3% 24 7 250.8% Total Income 2,988 2,312 29.2% 1,034 874 18.3% EBITDA 423 290 45.9
Slide 20: Corporate Information
zm Zeal & Innovation in Medicine CORPORATE INFORMATION
Slide 21: Shareholding
SHAREHOLDING Overall Shareholding % Public Shareholding % During Q3, ZIM Laboratories Limited was listed on the National Stock 5% Exchange of India (NSE) 5% The company issued Bonus Shares in the ratio of 2 (two) shares for 1 67% (one) existing share 33% 35% Promoter Group shareholding is free 22% o
Slide 22: Share Price Movement
SHARE PRICE MOVEMENT ZIM Closing Share Price (BSE) vs BSE S&P Healthcare Index 26570 106 97 87.3 85.3 80.6 78.6 73.3 75.3 23531 23341 61.6 54.6 53 23034 51 49.6 48.3 46.6 46 41.3 39.3 38.6 21606 27 27.6 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 Jan-22 Feb-22 Mar-22 Apr-22 May-22
Slide 23: Thank You
2.mn 1 THANK YOU